Editorial
Open access
Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval
Medicine
Abstract
use of pacritinib in transplant-eligible MF patients. The study showed that pacri-tinib provided symptomatic benefit and that its use pre-transplant does not preclude alloHCT.